Dravet syndrome therapeutics: where are we, what works, and what's next?

Dravet Syndrome (DS) is a devastating developmental and epileptic encephalopathy marked by early refractory seizures and pervasive symptoms impacting cognition, behavior, motor function, sleep, and autonomic control. This review appraises established and emerging therapeutics, tracing the field's shift from broad antiseizure medications to gene-modifying strategies. Sustained progress hinges on targeting defined nodes in DS pathophysiology to improve the whole patient, not just seizure control.

We searched PubMed and ClinicalTrials.gov for 'Dravet syndrome' OR 'DS' AND 'pharmacotherapy' AND 'treatments' OR "therapeutics. We prioritized DS-specific randomized controlled trials, open-label extensions, structured reviews, network meta-analyses, and natural-history cohorts to assess clinical use, efficacy, and safety, and integrated preclinical in vitro/in vivo models to map mechanisms of action.

DS therapeutics are converging on disease modification: gene-regulatory approaches lead, and targeted small molecules extend, mechanism-based care. We outline a practical precision ecosystem with four pillars: (i) early genetic screening with genotype-informed prediction, (ii) pharmacogenomic-guided prescribing, (iii) patient-specific variant modeling to clarify mechanism and optimize drug selection, and (iv) targeted restorative gene-modifying therapies that address causation. Together, these elements shift DS care toward individualized, mechanism-matched treatment providing seizure control as well as measurable gains in communication, learning, mobility, sleep, and autonomic stability.